Pipeline

Faron’s focus is on the development of bexmarilimab, a first-in-class, humanized monoclonal antibody that binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, and a novel immune checkpoint target for drug development. With a focus on hematological malignancies and solid tumors, our ambition is to bring the promise of immunotherapy to a broader population.